These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38239037)

  • 1. In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease.
    da Silva ANR; Pereira GRC; Bonet LFS; Outeiro TF; De Mesquita JF
    J Cell Biochem; 2024 Mar; 125(3):e30523. PubMed ID: 38239037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
    Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
    Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
    Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
    ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
    Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
    Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
    Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
    J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
    Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
    Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrillation of α-synuclein triggered by bacterial endotoxin and lipid vesicles is modulated by N-terminal acetylation and familial Parkinson's disease mutations.
    Monteiro Neto JR; Lima VA; Follmer C
    FEBS J; 2024 Mar; 291(6):1151-1167. PubMed ID: 38069536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis.
    Kim M; Bezprozvanny I
    Biochem Biophys Res Commun; 2023 Sep; 671():18-25. PubMed ID: 37290280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
    Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
    Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
    Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
    Vinueza-Gavilanes R; Íñigo-Marco I; Larrea L; Lasa M; Carte B; Santamaría E; Fernández-Irigoyen J; Bugallo R; Aragón T; Aldabe R; Arrasate M
    Neurobiol Dis; 2020 Apr; 137():104781. PubMed ID: 31991248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational investigation on the effects of H50Q and G51D mutations on the α-Synuclein aggregation propensity.
    Sanjeev A; Mattaparthi VSK
    J Biomol Struct Dyn; 2018 Jul; 36(9):2224-2236. PubMed ID: 28650719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease.
    Tenreiro S; Reimão-Pinto MM; Antas P; Rino J; Wawrzycka D; Macedo D; Rosado-Ramos R; Amen T; Waiss M; Magalhães F; Gomes A; Santos CN; Kaganovich D; Outeiro TF
    PLoS Genet; 2014 May; 10(5):e1004302. PubMed ID: 24810576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
    Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
    Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.
    van der Gaag BL; Deshayes NAC; Breve JJP; Bol JGJM; Jonker AJ; Hoozemans JJM; Courade JP; van de Berg WDJ
    Acta Neuropathol; 2024 Jan; 147(1):14. PubMed ID: 38198008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.